Hypothesis

Senescent memory B cells function as a rheostat that tempers germinal center reactions by secreting a senescence‑associated secretory phenotype (SASP) rich in TGF‑β1 and IL‑10, which epigenetically suppresses activation‑induced cytidine deaminase (AID) in neighboring naïve and centroblast B cells. This restraint limits off‑target somatic hypermutation (SHM) and curtails the emergence of autoreactive clones, thereby preserving peripheral B‑cell homeostasis at the cost of reduced antibody diversity—a trade‑off that becomes maladaptive with age as senescent B‑cell accumulation overly dampens AID activity.

Mechanistic rationale

• Aged B cells exhibit senescence markers (p16^INK4a^, p21^Cip1^) and a proinflammatory SASP [4]. Recent work shows that young senescent fibroblasts enrich for developmental and regenerative programs, suggesting SASP can be context‑dependent [7].
• TGF‑β1 and IL‑10 are known to induce DNA methylation of the Aicda promoter and to decrease AID transcription in B cells (https://doi.org/10.1016/j.immuni.2020.05.015).
• Homeostatic proliferation of long‑lived memory B cells suppresses lymphopoiesis, reversible upon depletion [6]; this effect may be mediated by SASP‑driven inhibition of AID‑dependent proliferation rather than mere niche competition.
• Reduced SHM quality in aged individuals, especially replacement mutations in Vκ4 CDRs/FRs, correlates with lower IL‑7, E2A, RAG, and lambda‑5 expression [1][2] and shows sex‑biased decline in Phase II SHM [3]; we propose that part of this deficit stems from extrinsic SASP‑mediated AID suppression rather than solely intrinsic transcriptional decay.

Testable predictions

1. Co‑culture of naïve B cells with senescent memory B cells (or conditioned senescent B‑cell supernatant) will decrease Aicda mRNA and protein levels, increase promoter methylation of Aicda, and lower SHM frequency in a TGF‑β1/IL‑10‑dependent manner (neutralizing antibodies abolish the effect).
2. In aged mice, genetic ablation of p16^INK4a^‑expressing B cells (using p16‑3MR or CD19‑Cre; p16^fl/fl^) will elevate AID activity in germinal centers, increase replacement mutations in Vκ regions, and improve neutralizing antibody titers against a novel antigen, but will also raise the frequency of autoreactive anti‑nuclear antibody clones detectable by ELISA or HEp‑2 staining.
3. Single‑cell multi‑omics of B cells from young vs. old humans will reveal a senescent B‑cell cluster (high CDKN2A/CDKN1A, SASP genes) whose proximity score to naïve B cells inversely correlates with AICDA expression and SHM scores.
4. Adoptive transfer of senescent B‑cell‑derived exosomes into young recipients will recapitulate the AID‑suppressive phenotype, an effect blocked by exosomal TGF‑β1 or IL‑10 inhibition.

Falsifiability If senescent B‑cell depletion does not alter AID activity, SHM quality, or autoantibody prevalence, or if SASP neutralization fails to rescue AID expression in vitro, the hypothesis would be refuted, supporting the view that age‑related SHM decline is driven solely by intrinsic transcriptional programs.

Broader impact Reframing senescent B cells as active negotiators of antibody‑gene stability suggests that senolytic strategies must consider the immunoregulatory SASP they provide; combined low‑dose SASP modulation may preserve the beneficial restraint while alleviating the proliferative block that underlies immunosenescence.